Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.66)
# 786
Out of 5,150 analysts
17
Total ratings
64.29%
Success rate
6.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Overweight | $94 → $91 | $38.61 | +135.72% | 2 | Mar 4, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $200 → $266 | $167.88 | +58.45% | 2 | Mar 3, 2026 | |
| SRZN Surrozen | Initiates: Overweight | $40 | $26.45 | +51.26% | 1 | Feb 19, 2026 | |
| WVE Wave Life Sciences | Maintains: Overweight | $34 → $41 | $13.44 | +205.06% | 2 | Feb 5, 2026 | |
| KRRO Korro Bio | Upgrades: Overweight | $21 | $10.75 | +95.35% | 2 | Jan 28, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $39 → $35 | $20.16 | +73.61% | 2 | Jan 13, 2026 | |
| XNCR Xencor | Maintains: Overweight | $40 → $42 | $12.02 | +249.42% | 2 | Nov 6, 2025 | |
| INVA Innoviva | Maintains: Overweight | $29 → $31 | $22.30 | +39.01% | 2 | Nov 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $3.94 | +77.89% | 1 | Oct 2, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $52 | $3.94 | +1,219.80% | 1 | Jul 11, 2025 |
Harrow
Mar 4, 2026
Maintains: Overweight
Price Target: $94 → $91
Current: $38.61
Upside: +135.72%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $200 → $266
Current: $167.88
Upside: +58.45%
Surrozen
Feb 19, 2026
Initiates: Overweight
Price Target: $40
Current: $26.45
Upside: +51.26%
Wave Life Sciences
Feb 5, 2026
Maintains: Overweight
Price Target: $34 → $41
Current: $13.44
Upside: +205.06%
Korro Bio
Jan 28, 2026
Upgrades: Overweight
Price Target: $21
Current: $10.75
Upside: +95.35%
Apellis Pharmaceuticals
Jan 13, 2026
Maintains: Overweight
Price Target: $39 → $35
Current: $20.16
Upside: +73.61%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $40 → $42
Current: $12.02
Upside: +249.42%
Innoviva
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $31
Current: $22.30
Upside: +39.01%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $3.94
Upside: +77.89%
Tvardi Therapeutics
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $3.94
Upside: +1,219.80%